Enzon Pharmaceuticals, Inc. (ENZN) - NASDAQ
  • Jun. 5, 2013, 9:11 AM
    Premarket gainers: KNDI +33%. AMBA +7%. AVNR +7%.
    Losers: ENZN -46%. TSL -8%. JASO -7%. NMR -6%
    | Jun. 5, 2013, 9:11 AM
  • Apr. 24, 2013, 11:27 AM

    Enzon Pharmaceuticals (ENZN -11.5%) flips an early pre-market gain to trade lower after the company unveiled a special dividend, a move that comes as the biopharmaceutical company concluded an earlier review of strategic alternatives and a workforce reduction. Late last year, Carl Icahn divulged a 13.3% stake in the company, and was taking an active interest in its operations and direction.

    | Apr. 24, 2013, 11:27 AM
  • Apr. 23, 2013, 6:38 PM
    Enzon Pharmaceuticals (ENZN) declares special dividend of $1.60/share. For shareholders of record May 07. Payable June 04. Ex-div date May 03. (PR)
    | Apr. 23, 2013, 6:38 PM | 8 Comments
  • Apr. 23, 2013, 5:48 PM
    After-hours top gainers, as of 5:15 p.m.: IRBT +14%. ENZN +7%. YUM +6%. BRCM +5%. AAPL +5%.
    After-hours top losers: VOCS -30%. UIS -16%. DV -12%. AWAY -8%. PNRA -6%.
    | Apr. 23, 2013, 5:48 PM
  • Mar. 27, 2013, 10:42 AM
    Enzon Pharmaceuticals (ENZN -2.8%) hits a new 52-week low after disclosing in a regulatory filing late yesterday that it's reducing its workforce from 19 employees to 12. It expects to incur about $1.3M in charges related to the reduction in force, due to cash expenditures for one-time employee termination benefits and associated costs. The company expects to record the charges and complete the reduction by the end of Q1.
    | Mar. 27, 2013, 10:42 AM | 1 Comment
  • Mar. 19, 2013, 6:39 AM
    Enzon Pharmaceuticals (ENZN): Q4 EPS of -$0.11. Revenue of $10.6M. (PR)
    | Mar. 19, 2013, 6:39 AM
  • Dec. 17, 2012, 10:33 AM
    Shares of Enzon Pharmaceuticals (ENZN) have resumed trading following an earlier halt, and the shares are currently up 5.4%. Carl Icahn has a 13.29% stake in Enzon, and disclosed in November that he and his associates wanted to discuss the operations and direction of the company.
    | Dec. 17, 2012, 10:33 AM
  • Dec. 17, 2012, 9:10 AM
    Premarket gainers: JVA +12%. ENZN +10%. CBMX +10%. LXRX +9%. TROX +6%. CTIC +5%.
    Losers: NBG -13%. CLWR -11%. SQNM -6%.
    | Dec. 17, 2012, 9:10 AM
  • Dec. 17, 2012, 7:28 AM

    Enzon Pharmaceuticals (ENZN) halts clinical development and has hired Lazard to explore a sale of the company. The move comes about 2 weeks after Carl Icahn renewed his push for a change in direction. Shares halted. (PR)

    | Dec. 17, 2012, 7:28 AM
  • Dec. 6, 2012, 12:45 PM
    Midday top 10 gainers: BSDM +28%. EPHC +27%. MBLX +22%. INPH +18%. NVGN +18%. UEPS +17%. HITK +13%. CZR +11%. MITK +11%. CVO +11%.
    Midday top 10 Losers: ENZN -30%. TIGR -19%. SCMR -17%. NBY -16%. LFVN -14%. WEBM -14%. SNFCA -13%. KBW -13%. VRA -12%. HF -11%.
    | Dec. 6, 2012, 12:45 PM
  • Dec. 6, 2012, 9:10 AM
    Premarket gainers: WLT +7%. ZNGA +6%. AKAM +5%.
    Losers: ENZN -28%. VRA -10%. MW -10%. COST -7%. ERJ -6%. LFVN -6%. LVS -5%.
     
    | Dec. 6, 2012, 9:10 AM
  • Nov. 29, 2012, 5:34 PM
    Enzon Pharmaceuticals (ENZN) declares special dividend of $2.00/share. For shareholders of record Dec 10. Payable Dec 21. Ex-div date Dec 06. (PR)
    | Nov. 29, 2012, 5:34 PM
  • Nov. 28, 2012, 3:29 PM

    Enzon Pharmaceuticals (ENZN -0.6%) slip after activist investor Carl Icahn files an amended 13D requesting a discussion on the company's operations and direction, as well as the it's plans to preserve shareholder value.

    | Nov. 28, 2012, 3:29 PM
  • Feb. 28, 2012, 5:42 PM
    Enzon Pharmaceuticals (ENZN) discloses it has appointed Icahn Capital's George Hebard to a new board seat. Carl Icahn has long pushed for a management overhaul at Enzon.
    | Feb. 28, 2012, 5:42 PM
  • Dec. 16, 2010, 9:00 AM

    Premarket gainers: CUR +11%. CCME +9%. UEC +7%. VG +7%. ENZN +7%. NVAX +6%. ERIC +4%. ARO +4%. MORT +4%. PCBC +4%. MCP +4%.
    Losers: RGS -8%.

    | Dec. 16, 2010, 9:00 AM
  • Nov. 9, 2009, 8:33 AM
    Enzon Pharmaceuticals (ENZN) to sell its specialty pharmaceutical business to the sigma-tau Group for $300M plus another $27M if it hits certain milestones. ENZN will also retain royalties of 5-10%on incremental net sales above a baseline amount. ENZN is halted.
    | Nov. 9, 2009, 8:33 AM
Company Description
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. The company engages in the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Its drug-development programs utilize two platforms such as customized PEGylation linker technology and... More
Sector: Healthcare
Industry: Biotechnology
Country: United States